Multimodal Treatment of Cholangiocarcinoma

Dirk Graf, Verena Keitel, Dieter Häussinger


Cholangiocarcinomas (CCA) belong to a heterogeneous group of malignant tumours, which arise from the biliary tree via malignant transformation of cholangiocytes, hepatocytes or from hepatic progenitor cells. Even though clinical diagnosis and management of CCA improved significantly during the last decades, this malignant disease is still associated with a dismal prognosis. More and more multimodal therapeutic strategies are integrated into the treatment schedule. In selected patients treatment allocation should be based on a personalized medicine rather than guideline-based medicine by a multidiciplinary board. This review summarizes the current epidemiology, classification, diagnosis and management of CCAs and illustrates controversial areas of therapeutic strategies.


cholangiocarcinoma, ALPSS, liver transplantation, radiofrequency ablation, transarterial chemoembolization, chemotherapy

Full Text:



Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002;37:806-13.

Sripa B, Pairojkul C. Cholangiocarcinoma: lessons from Thailand. Curr Opin Gastroenterol. 2008;24:349–356.

DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245:755-762.

Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13:261-280.

Tayler-Robinson TD, Toledano MB, Arora S. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 2001;48:816-820.

Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 2013;145:1215-29.

Tyson GL and El-Serag HB. Risk Factors of Cholangiocarcinoma. Hepatology 2011; 54:173-184.

Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248:84-96.

Khan SA, Emadossadaty S, Ladep N, Thomas HC, Elliott P, Taylor-Robinson SD et al. Rising trends in cholangiocarcinom: is the ICD classification system misleading us. J Hepatol. 2012;56:848-54.

Fan B, Malato Y, Calvisi DF, Naqvi S, Razumilava N, Ribback S et al. Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest. 2012;122:2911-5.

Guest RV, Boulter L, Kendall TJ, Minnis-Lyons SE, Walker R, Wigmore SJ et al. Cell lineage tracing reveals a biliary origin of intrahepatic cholangiocarcinoma. Cancer Res. 2014;74:1005-10.

Sia D, Villanueva A, Friedman SL, Llovet JM. Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. Gastroenterology. 2017;152:745-761.

Bismuth H, Nakache R, Diamond T. Management strategies in resection of hilar cholangiocarcinoma. Ann Surg., 1992;215:31-38.

Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996;224:463–473.

Rizvi S, Gores GJ. Emerging Molecular Therapeutic Targets for Cholangiocarcinoma. J Hepatol. 2017 Apr 4. [Epub ahead of print].

Gera S, Ettel M, Acosta-Gonzalez G, Xu R. Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma. World J Hepatol. 2017; 9:300-309.

Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;8:512–522.

Claessen MM, Vleggaar FP, Tytgat KM, Siersema PD, van Buuren HR. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol. 2009;50:158-64.

Cunningham SC, Choti MA, Bellavance EC, Pawlik TM. Palliation of hepatic tumours. Surg Oncol. 2007;16:277-291.

Farley DR, Weaver AL, Nagorney DM. Natural history of unresected cholangiocarcinoma: patient outcome after noncurative intervention. Mayo Clin Proc. 1995;70:425-429.

Zhou Y, Liu S, Wu L, Wan T. Survival after surgical resection of distal cholangiocarcinoma: A systematic review and meta-analysis of prognostic factors. Asian J Surg. 2017;40:129-138.

Nathan H, Pawlik TM, Wolfgang CL, Choti MA, Cameron JL, Schulick RD. Trends in survival after surgery for cholangiocarcinoma: A 30-year population-based SEER database analysis. J Gastrointest Surg. 2007;11:1488-97.

Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016; 27:28-37.

Saini S. Imaging of hepatobiliary tract. N Engl J Med. 1997;336:1889-1894.

Yamasaki S. Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J Hepatobiliary Pancreat Surg. 2003;10:288-291.

Lim JH, Park CK. Pathology of cholangiocarcinoma. Abdom Imaging. 2004;29:540-547.

Navaneethan U, Njei B, Venkatesh PG, Vargo JJ, Parsi M. Fluorescence in situ hybridization for diagnosis of cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointest Endosc. 2014;79:943-950.

Draganov PV, Chauhan S, Wagh MS, Gupte AR, Lin T, Hou W et al. Diagnostic accuracy of conventional and-cholangioscopy-guided sampling of indeterminate biliary lesions at the same ERCP: a prospective, long-term follow-up study. Gastrointest Endosc. 2012;75:347-353.

Shen WF, Zhong W, Xu F, Kan T, Geng L, Xie F et al. Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma. World J Gastroenterol 2009; 15:5976-82.

Nakeeb A, Lipsett PA, Lillemoe KD, Fox-Talbot MK, Coleman J, Cameron JL et al. Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma. Am J Surg. 1996;171:147-153.

Bergquist JR, Ivanics T, Storlie CB, Groeschl RT, Tee MC, Habermann EB et al. Implications of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic cholangiocarcinoma: A national cohort analysis. J Surg Oncol. 2016;114:475-82.

Ono A, Fujimoto A, Yamamoto Y, Akamatsu S, Hiraga N, Imamura M et al. Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy. Cell Mol Gastroenterol Hepatol. 2015;1:516-534.

Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A (eds.). AJCC Cancer Staging Manual. New York: Springer; 2010.

Amin MB, Edge SB, Greene FL, Byrd DR, Brookland R, Washington MK, Gershenwald HE, (eds). AJCC Cancer Staging Manual 8th, AJCC Chicago: Springer 2017.

Sano T, Shimada K, Sakamoto Y, Yamamoto J, Yamasaki S, Kosuge T. One hundred two consecutive hepatobiliary resections for perihilar cholangiocarcinoma with zero mortality. Ann Surg. 2006;244:240-7.

Ustundag Y, Bayraktar Y. Cholangiocarcinoma: a compact review of the literature.

World J Gastroenterol. 2008;14:6458-66.

Nuzzo G, Giuliante F, Ardito F, De Rose AM, Vellone M, Clemente G et al. Intrahepatic cholangiocarcinoma: prognostic factors after liver resection. Updates Surg. 2010;62:11-19.

Hasegawa S, Ikai I, Fujii H, Hatano E, Shimahara Y. Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications. World J Surg. 2007;31:1256-63.

Corvera CU, Weber SM, Jarnagin WR. Role of laparoscopy in the evaluation of biliary tract cancer. Surg Oncol Clin N Am. 2002;11:877-91.

Tsao JI, Nimura Y, Kamiya J, Hayakawa N, Kondo S, Nagino M et al. Management of hilar cholangiocarcinoma: comparison of an American and a Japanese experience. Ann Surg. 2000;232:166-174.

Esnaola NF, Meyer JE, Karachristos A, Maranki JL, Camp ER, Denlinger CS. Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma. Cancer 2016;122:1349-69.

Klempnauer J, Ridder GJ, von Wasielewski R, Werner M, Weimann A, Pichlmayr R. Resectional surgery of hilar cholangiocarcinoma: a multivariate analysis of prognostic factors. J Clin Oncol 1997;15:947-54.

Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Kondo N et al. Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma. Ann Surg Oncol. 2011;18:651-8.

Matso K, Roche FG, Ito K, D'Angelica MI, Allen PJ, Fong Y et al. The Blumgart preoperative staging system for hilar cholangiocarcinoma: analysis of resectability and outcomes in 380 patients. J Am Coll Surg. 2012;215:343-355.

Hemming AW, Reed AI, Howard RJ, Fujita S, Hochwald SN, Caridi JG et al. Preoperative portal vein embolization for extended hepatectomy. Ann Surg. 2003; 237:686-691.

Abdalla EK, Barnett CC, Doherty D, Curely SA, Vauthey JN. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch. Surg. 2002;137:675-680.

Olthof PB, Coelen RJS, Wiggers JK, Groot Koerkamp B, Malago M, Hernandez-Alejandro R et al. High mortality after ALPPS for perihilar cholangiocarcinoma: case-control analysis including the first series from the international ALPPS registry. HPB (Oxford) 2017;19:381-387.

Dodson RM, Weiss MJ, Cosgrove D, Herman JM, Kamel I, Anders R et al. Intrahepatic cholangiocarcinoma: management options and emerging therapies. J Am Coll Surg 2013; 217:736-750.

de Jong MC, Nathan H, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol 2011;29:3140-3145.

Ribero D, Pinna AD, Guglielmi A, Panti A, Nuzzo G, Giulini SM et al. Surgical approach for long-term survival of patients with intrahepatic cholangiocarcinoma: A multi-institutional analysis of 434 patients. Arch Surg 2012;147:1107-13.

Carpizo DR, D'Angelica M. Management and extent of resection for intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am 2009;18:289-305.

Chamberlain RS, Blumgart LH. Hilar cholangiocarcinoma: a review and commentary. Ann Surg Oncol. 2000;7:55-66.

Nagino M, Nimura Y, Nishio H, Ebata T, Igami T, Matsushita M et al. Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma: an audit of 50 consecutive cases. Ann Surg. 2010;252:115-123.

Witzigmann H, Berr F, Ringel U, Caca K, Uhlmann D, Schoppmeyer K et al. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection. Ann Surg. 2006;244:230–239.

van den Broek MA, van Dam RM, Malagó M, Dejong CH, van Breukelen GJ, Olde Damink SW. Feasibility of randomized controlled trials in liver surgery using surgery related mortality or morbidity as endpoint. Br J Surg. 2009;96:1005–1014.

Gerhards MF, van Gulik TM, de Wit LT, Obertop H, Gouma DJ. Evaluation of morbidity and mortality after resection for hilar cholangiocarcinoma--a single center experience. Surgery. 2000;127:395–404.

Blechacz B. Cholangiocarcinom: Current knowledge and new developments. Gut and Liver 2017;11:13-26.

Laurent A, Tayar C, Cherqui D. Cholangiocarcinoma: preoperative biliary drainage (Con). HPB (Oxford) 2008;10:126-129.

Nimura Y. Preoperative biliary drainage before resection for cholangiocarcinoma (Pro). HPB (Oxford) 2008; 10:130-133.

van der Gaag NA, Rauws EA, van Eijck CH, Bruno MJ, van der Harst E, Kubben FJ et al. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med. 2010; 362:129–37.

Figueras J, Llado L, Valls C. Changing strategies in diagnosis and management of hilar cholangiocarcinoma. Liver Transpl. 2000;6:786-794.

Liu F, Li Y, Wei Y, Li B. Preoperative biliary drainage before resection for hilar cholangiocarcinoma: whether or not? A systematic review. Dig Dis Sci. 2011;56:663-72.

Walter T, Ho CS, Horgan AM, Warkentin A, Gallinger S, Greig PD et al. Endoscopic or percutaneous biliary drainage for Klatskin tumors? J Vasc Interv Radiol 2013; 24:113-121.

Paik WH, Loganathan N, Hwang JH. Preoperative biliary drainage in hilar cholangiocarcinoma: When and how? World J Gastrointest Endosc 2014; 6:68-73.

Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut 2012;61:1657–1669.

Celotti A, Solaini L, Montori G, Coccolini F, Tognali D, Baiocchi G. Preoperative biliary drainage in hilar cholangiocarcinoma: Systematic review and meta-analysis. Eur J Surg Oncol. 7 Apr 18. pii: S0748-7983(17)30443-2.

Cai Y, Tang Q, Xiong X, Li F, Ye H, Song P, Cheng N. Preoperative biliary drainage versus direct surgery for perihilar cholangiocarcinoma: A retrospective study at a single center. Biosci Trends. 2017 May 22. doi: 10.5582/bst.2017.01107. [Epub ahead of print]

Mansour JC, Aloia TA, Crane CH, Heimbach JK, Nagino M, Vauthey JN. Hilar cholangiocarcinoma: expert consensus statement. HPB (Oxford) 2015;17: 691–699.

Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012:308:1934-40.

Primrose JN, Fox R, Palmer DH, Prasad R, Mirza D, Anthoney DA et al. Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study. J Clin Oncol. 2017:35; Abstr. 4006

Edeline J, Bonnetain F, Phelip JM, Watelet J, Hammel P, Joly JP et al. Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODRIGE 12-ACCORD 18 (Unicancer GI) phase III trial. J Clin Oncol. 2017:35 (suppl 4S) Abstract 225.

Tran TB, Bal CK, Schaberg K, Longacre TA, Chatrath BS, Poultsides GA. Locally advanced intrahepatic cholangiocarcinoma: Complete pathologic response to neoadjuvant chemotherapy followed by left hepatic trisectionectomy and caudate lobectomy. Dig Dis Sci 2015;60:3226-3229.

Grendar J, Grendarova P, Sinha R, Dixon E. Neoadjuvant therapy for downstaging of locally advanced hilar cholangiocarcinoma: a systematic review. HPB (Oxford). 2014 Apr;16(4):297-303.

Rosen CB, Heimbach JK, Gores GJ. Surgery for cholangiocarcinoma: the role of liver transplantation. HPB (Oxford) 2008;10:186-9.

Petrowsky H, Hong JC. Current surgical management of hilar and intrahepatic cholangiocarcinoma: the role of resection and orthtotopic liver transplantation. Transplant Proc. 2009;41:4023-35.

Sapisochin G, Facciuto M, Rubbia-Brandt L, Marti J, Mehta N, Yao FY et al. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. Hepatology 2016;64:1178-88.

Rea DJ, Heimbach JK, Rosen CB, Haddock MG, Alberts SR, Kremers WK, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg. 2005;242:451–461.

Darwish MS, Kim WR, Therneau T, Gores GJ, Rosen CB, Martenson JA et al. Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma. Hepatology 2012;56:972-981.

Darwish MS, Kim WR, Harnois DM, Douglas DD, Burton J, Kulik LM, Botha JF et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012;143:88-98.

Kim YI, Park JW, Kim BH, Woo SM, Kim TH, Koh YH et al. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma. Radiat Oncol 2013;8:292-98.

Ben-David MA, Griffith KA, Abu-Isa E, Lawrence TS, Knol J, Zalupski M et al. External-beam radiotherapy for localized extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 2006;66:772-9.

Jung DH, Kim MS, Cho CK, Yoo HJ, Jang WI, Seo YS et al. Outcomes of stereotactic body radiotherapy for unresectable primary or recurrent cholangiocarcinoma. Radiat Oncol J 2014;32:163-9.

Mahadevan A, Dagoglu N, Mancias J, Raven K, Khwaja K, Tseng JF et al. Stereotactic Body Radiotherapy (SBRT) for intrahepatic and hilar cholangiocarcinoma. J Cancer 2015;6:1099-1104.

Polistina FA, Guglielmi R, Baiocchi C, Francescon P, Scalchi P, Febbraro A et al. Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, non-metastatic, locally advanced hilar cholangiocarcinoma. Results of a five year experience. Radiother Oncol. 2011;99:120-123.

Boehm LM, Jayakrishnan TT, Miura JT, Zacharias AJ, Johnston FM, Turaga KK et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol. 2015;11:213-220.

Hyder O, Marsh JW, Salem R, Petre EN, Kalva S, Liapi E et al. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol. 2013;20:3779-3786.

Rafi S, Piduru SM, El-Rayes B, Kauh JS, Kooby DA, Sarmiento JM et al. Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study. Cardiovasc Intervent Radiol 2013:36:440-448.

Hoffmann RT, Paprottka PM, Schön A, Bamberg F, Haug A, Dürr EM et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinomas: factors associated with prolonged survival. Cardiovasc Intervent Radiol 2012;35:105-116.

Mouli S, Memon K, Baker T, Benson AB, Mulcahy MF, Gupta R et al. Yttrium-90 Radioembolization for Intrahepatic Cholangiocarcinoma: Safety, Response, and Survival Analysis. J Vasc Interv Radiol. 2013;24(8):1227-34.

Al-Adra DP, Gill RS, Axford SJ, Shi X, Kneteman N, Liau SS. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur J Surg Oncol. 2015;41(1):120-7.

Han K, Ko HK, Kim KW, Won HJ, Shin YM, Kim PN. Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma: systematic review and meta-analysis. J Vasc Interv Radiol. 2015;26(7):943-8

Kiefer MV, Albert M, McNally M, Robertson M, Sun W, Fraker D et al. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. Cancer 2011;117:1498–505.

Park SY, Kim JH, Yoon HJ, Lee IS, Yoon HK, Kim KP. Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma. Clin Radiol. 2011; 66:322–28.

Vogl TJ, Naguib NN, Nour-Eldin NE, Bechstein WO, Zeuzem S, Trojan J et al. Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: results and prognostic factors governing treatment success. Int J Cancer 2012; 131:733–40.

Zoepf T, Jakobs R, Arnold JC, Apel D, Riemann JF. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol. 2005; 100:2426-2430.

Ortner ME, Caca K, Berr F, Liebetruth J, Mansmann U, Huster D et al. Successfull photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003;125:1355-1363.

Laquière A, Boustière C, Leblanc S, Penaranda G, Désilets E, Prat F. Safety and feasibility of endoscopic biliary radiofrequency ablation treatment of extrahepatic cholangiocarcinoma. Surg. Endosc 2016;30:1242–1248.

Dolak W, Schreiber F, Schwaighofer H, Gschwantler M, Plieschnegger W, Ziachehabi A et al. Endoscopic radiofrequency ablation for malignant biliary obstruction: a nationwide retrospective study of 84 consecutive applications. Surg. Endosc. 2014; 28: 854–860.

Nehls O, Oettle H, Hartmann JT, Hofheinz RD, Hass HG, Horger MS et al. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer 2008;98:309-15.

Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A et al. ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81.

Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer. A comparative multicentre study in Japan. Br J Cancer 2010;103:469-474.

Glimelius B, Hoffman K, Sjödén PO, Jacobsson G, Sellström H, Enander LK, Linné T, Svensson C et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996;7:593-600.

Sharma A, Dwary AD, Mohanti BK, Deo SV, Pal S, Sreenivas V et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol. 2010;28:4581-6.

Ducreux M, Van Cutsem E, Van Laethem JL, Gress TM, Jeziorski K, Rougier P et al. A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial.Eur J Cancer 2005;41:398-403.

Alberts SR, Al-Khatib H, Mahoney MR, Burgart L, Cera PJ, Flynn PJ et al. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer 2005;103:111-8.

Takada T, Nimura Y, Katoh H, Nagakawa T, Nakayama T, Matsushiro T et al. Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial. Hepatogastroenterology 1998;45:2020-6.

André T, Reyes-Vidal JM, Fartoux L, Ross P, Leslie M, Rosmorduc O et al. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer 2008;99:862-7.

Eckel F, Schmid RM: Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials.Br J Cancer 2007;96:896–902.

Lamarca A, Hubner RA, David Ryder W, Valle JW. Second-line chemotherapy in advanced biliary cancer: a systemic review. Ann Oncol. 2010;11:1142-1148.

Bupathi M, Ahn DH, Bekaii-Saab. Therapeutic options for intrahepatic cholangiocarcinoma. HepatoBiliary Surg Nutr. 2017;6:91-100.

Ahn DH, Bekaii-Saab T. Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications. Gastrointest Oncol. 2017;8:293-301.

Bang YJ, Doi T, De Braud F, Piha-Paul S, Hollebecque A, Abdul Razak AR et al. Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: interim results of KEYNOTE-028. ESMO 40, ECCO 18, The European Cancer Congress 2015, Abs 525.

Javle MM, Shroff RT, Zhu A, Sadeghi S, Choo SP, Borad MJ et al. A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy. J Clin Oncol. 34, 2016 (suppl 4S; abstr. 335)

Burris H, Mellinghoff IK, Maher E, et al. The first reported results of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a Phase I study of patients with advanced IDH1-mutant solid tumors, including gliomas. Molecular Targets and Cancer Therapeutics 2015, Abstract PL04-05



  • There are currently no refbacks.
Copyright 2016. All rights reserved.